Amgen acquires Onyx Pharmaceuticals for $10.4 billion.
Breaking News
Pharmaceutical giants Pfizer, AstraZeneca and Novartis are among those to propose bids for Onyx Pharmaceuticals.
After its rejection of the Amgen bid, Onyx is now fielding bids from Bayer and other pharmaceutical firms.
Pharmaceutical companies Novartis and Pfizer showing interest in Onyx
Onyx Pharmaceuticals Inc stated that it has rejected the unsolicited bid from Amgen Inc priced at US$120 per share piece.
Amgen announced an offered acquisition for biotech Onyx Pharmaceuticals at US$120 per share piece.
Subscribe to VCpost newsletter
Most Popular
- Doctors Raise Concerns Over Proposed Capital Gains Tax Changes
- How to Get IRS Unclaimed Tax Refunds: Here's What to Do If You Think You Have Pending Payments
- Tesla Shareholder Asks Judge to Prevent Elon Musk From Moving Pay Fight to Texas to Evade Delaware Ruling
- Celebrity Designer Nancy Gonzalez Jailed for Smuggling Crocodile, Python Handbags
- Kroger and Albertsons to Sell off 166 Stores in Effort to Gain Approval for Their $25 Billion Merger
- Where's My Child Tax Credit 2024: When to Receive My Money After April 15 Tax Filing Deadline?
- Illinois Woman, Who Mysteriously Drowned After Giving $1.5 Million to Online Romance Scammers, Knew She'd 'End up Dead'
- Biden Administration Announces New Federal Rules: Airlines Required to Automatically Give Refunds for Delayed, Canceled Flights
